AbstractRecombinant lentiviral vectors pseudotyped with heterologous HIV-1 envelope glycoproteins allow rapid and accurate measurement of antibody-mediated HIV-1 neutralization. However, the neutralization phenotypes of envelope pseudoviruses have not been directly compared to isogenic replication competent HIV-1. We produced pseudoviruses expressing three different HIV-1 envelope glycoproteins and subcloned the same three env genes into a replication competent NL4-3 molecular clone. For each of the antibodies tested, the neutralization dose–response curves of pseudoviruses and corresponding replication competent viruses were similar. Thus, envelope pseudoviruses can be used to study the anti-HIV-1 neutralizing antibody response. A single p...
AbstractIn this study, progeny viruses of four HIV-1 molecular clones were tested for sensitivity to...
<p>(A) Comparison of XMRV and control HIV-1 pseudoviruses in yield (p24 accumulation) and infectivit...
OBJECTIVE: Using clinical isolates from a recent passive immunization trial with antibody 2G12, we p...
AbstractRecombinant lentiviral vectors pseudotyped with heterologous HIV-1 envelope glycoproteins al...
The absence of an effective humoral response contributes to the failure of controlling HIV-1 infecti...
AbstractNeutralization properties of human immunodeficiency virus (HIV-1) are often defined using ps...
In this study, we tested the hypothesis that donors with broadly cross-reactive HIV-1 neutralizing (...
AbstractIn this study, we tested the hypothesis that donors with broadly cross-reactive HIV-1 neutra...
Standardized assays to assess vaccine and antiviral drug efficacy are critical for the development o...
<div><p>Standardized assays to assess vaccine and antiviral drug efficacy are critical for the devel...
ABSTRACT Recently discovered broadly neutralizing antibodies (bNAbs) against HIV-1 demonstrate exten...
AbstractIn this study, progeny viruses of four HIV-1 molecular clones were tested for sensitivity to...
A human immunodeficiency virus type 1 (HIV-1) mutant lacking the V1 and V2 variable loops in the gp1...
A human immunodeficiency virus type 1 (HIV-1) mutant lacking the V1 and V2 variable loops in the gp1...
A human immunodeficiency virus type 1 (HIV-1) mutant lacking the V1 and V2 variable loops in the gp1...
AbstractIn this study, progeny viruses of four HIV-1 molecular clones were tested for sensitivity to...
<p>(A) Comparison of XMRV and control HIV-1 pseudoviruses in yield (p24 accumulation) and infectivit...
OBJECTIVE: Using clinical isolates from a recent passive immunization trial with antibody 2G12, we p...
AbstractRecombinant lentiviral vectors pseudotyped with heterologous HIV-1 envelope glycoproteins al...
The absence of an effective humoral response contributes to the failure of controlling HIV-1 infecti...
AbstractNeutralization properties of human immunodeficiency virus (HIV-1) are often defined using ps...
In this study, we tested the hypothesis that donors with broadly cross-reactive HIV-1 neutralizing (...
AbstractIn this study, we tested the hypothesis that donors with broadly cross-reactive HIV-1 neutra...
Standardized assays to assess vaccine and antiviral drug efficacy are critical for the development o...
<div><p>Standardized assays to assess vaccine and antiviral drug efficacy are critical for the devel...
ABSTRACT Recently discovered broadly neutralizing antibodies (bNAbs) against HIV-1 demonstrate exten...
AbstractIn this study, progeny viruses of four HIV-1 molecular clones were tested for sensitivity to...
A human immunodeficiency virus type 1 (HIV-1) mutant lacking the V1 and V2 variable loops in the gp1...
A human immunodeficiency virus type 1 (HIV-1) mutant lacking the V1 and V2 variable loops in the gp1...
A human immunodeficiency virus type 1 (HIV-1) mutant lacking the V1 and V2 variable loops in the gp1...
AbstractIn this study, progeny viruses of four HIV-1 molecular clones were tested for sensitivity to...
<p>(A) Comparison of XMRV and control HIV-1 pseudoviruses in yield (p24 accumulation) and infectivit...
OBJECTIVE: Using clinical isolates from a recent passive immunization trial with antibody 2G12, we p...